Jump to content

Draft:Ram Vishwakarma

From Wikipedia, the free encyclopedia

Ram Vishwakarma (born 1 July 1960) is an Organic Chemist, born in Orai in the state of Uttar Pradesh in India. He is currently working as a Distinguished Scientist at the Council of Scientific & Industrial Research (CSIR), New Delhi and the Central Drug Research Institute (CDRI), Lucknow. Prior to this assignment, he served as a director of CSIR-Indian Institute of Integrative Medicine, Jammu from 2009 to 2020.[1]

Career

[edit]

Ram Vishwakarma obtained B.Sc. and M.Sc. from Bundelkhand University in 1978 and 1980 respectively and Ph.D. in medicinal chemistry from CDRI Lucknow in 1986. After obtaining his doctorate, he worked at a CSIR lab for a few years, before joining his post-doctoral studies, in 1991, at the Cambridge University, England with Sir Alan Battersby FRS on biosynthesis of Cyanocobalamin (Vitamin B12) and related corrins and porphyrins. After completing his post-doctoral studies in 1993, he joined as a faculty at the National Institute of Immunology, New Delhi and established an active group on chemical biology of glycosylphosphatidylinositol (GPI) anchors. In 2005, he moved to Piramal Healthcare Mumbai, a leading pharmaceutical company. In early 2009, he joined as the director of CSIR-Indian Institute of Integrative Medicine, Jammu and initiated some major programs in the areas of new drug discovery (cancer, inflammation and infections) and national societal missions (Aroma and Phytopharmaceutical missions). In 2021, he took up a position of Distinguished Scientist at CSIR, New Delhi to mentor research projects on translational neuroscience.

His diverse research interests are in the areas of drug discovery, medicinal chemistry, organic synthesis, chemical glycobiology, and clinical development. He has made significant contributions in scientific research, therapeutic and vaccine development, preclinical and clinical development, establishing biotechnology incubation and innovation centers and societal missions. Some of his notable scientific contributions include, biosynthesis of cyanocobalamin (Vitamin B12) – porphyrin to corrin rearrangement,[2][3] chemical synthesis of Lipophosphoglycans of Leishmania parasitic species,[4][5][6] chemical synthesis of GPI anchors of Leishmania, Trypanosoma and Malaria parasites,[7][8] trans-bilayer flip-flop of the GPI biosynthetic intermediates,[9][10] synthesis of full-length phospholipomannan of Candida albicans,[11] nanoclustering of GPI-anchored proteins in the biological membranes,[12][13] discovery of isoform selective inhibitors[14] of Cyclin-dependent Kinases and Phosphatidylinositol-3-Kinases[15][16][17][18] for preclinical and clinical development. He has published over 250 original scientific papers in scholarly journals and 50 patents granted.[19]

Recognition and Professional Association

[edit]
  • Elected Fellow of the National Academy of Sciences, India
  • Sun Pharma (Ranbaxy) Research Award for Pharmaceutical Sciences[20]
  • Member of the Governing Body and Society of the CSIR (2018–2020)
  • Member of the International Editorial Advisory Board of "Journal of Medicinal Chemistry" of the American Chemical Society[21]
  • SFE-Zandu Award 2016 for significant contributions in Natural Products Chemistry[22]
  • Member of Genetic Engineering Approval Committee (GEAC) of the Ministry of Environment and Forests (Govt. of India) (2009–2011)
  • Member Program Advisory Committee (Organic-Chemistry) of the Department of Science and Technology (Govt. of India) (2004–2012)
  • Member of Task Force (Plant Biotechnology) of the Department of Biotechnology (Govt. of India) (2008–2012)
  • Invited lectures at the Gordon Research Conference (Glycobiology) in USA)
  • BOYSCAST-Fellowship of DST (Govt. of India) for the Chemical Sciences (1991–1993)

References

[edit]
  1. ^ Sansad TV (2014-03-05). Eureka with Ram Vishwakarma. Retrieved 2024-09-20 – via YouTube.
  2. ^ Li, Yongfu; Alanine, Alex I. D.; Vishwakarma, Ram A.; Balachandran, Sarala; Leeper, Finian J.; Battersby, Alan R. (January 1, 1994). "Biosynthesis of vitamin B12: mechanistic studies on the transfer of a methyl group from C-11 to C-12 and incorporation of 18O". Journal of the Chemical Society, Chemical Communications (21): 2507–2508. doi:10.1039/C39940002507 – via pubs.rsc.org.
  3. ^ Vishwakarma, Ram A.; Balachandran, Sarala; Alanine, Alex I. D.; Stamford, N. Patrick J.; Kiuchi, Fumiyuki; Leeper, Finian J.; Battersby, Alan R. (January 1, 1993). "Biosynthesis of porphyrins and related macrocycles. Part 41. Fate of oxygen atoms as precorrin-2 carrying eight labelled carboxyl groups (13C18O2H) is enzymatically converted into cobyrinic acid". Journal of the Chemical Society, Perkin Transactions 1 (23): 2893–2899. doi:10.1039/P19930002893 – via pubs.rsc.org.
  4. ^ Ruhela, Dipali; Vishwakarma, Ram A. (May 1, 2003). "Iterative Synthesis of Leishmania Phosphoglycans by Solution, Solid-Phase, and Polycondensation Approaches without Involving Any Glycosylation". The Journal of Organic Chemistry. 68 (11): 4446–4456. doi:10.1021/jo0341867. PMID 12762750 – via CrossRef.
  5. ^ Ruhela, Dipali; Vishwakarma, Ram A. (October 15, 2001). "Efficient synthesis of the antigenic phosphoglycans of the Leishmania parasite". Chemical Communications (19): 2024–2025. doi:10.1039/B106634J. PMID 12240271 – via pubs.rsc.org.
  6. ^ Upreti, Mani; Ruhela, Dipali; Vishwakarma, Ram A (August 25, 2000). "Synthesis of the Tetrasaccharide Cap Domain of the Antigenic Lipophosphoglycan of Leishmania donovani Parasite". Tetrahedron. 56 (35): 6577–6584. doi:10.1016/S0040-4020(00)00609-8 – via ScienceDirect.
  7. ^ Ali, Asif; Gowda, D. Channe; Vishwakarma, Ram A. (January 14, 2005). "A new approach to construct full-length glycosylphosphatidylinositols of parasitic protozoa and [4-deoxy-Man-III]-GPI analogues". Chemical Communications (4): 519–521. doi:10.1039/B414119A. PMID 15654389 – via pubs.rsc.org.
  8. ^ Ali, Asif; Vishwakarma, Ram A. (June 12, 2010). "Total synthesis of the fully lipidated glycosylphosphatidylinositol (GPI) anchor of malarial parasite Plasmodium falciparum". Tetrahedron. 66 (24): 4357–4369. doi:10.1016/j.tet.2010.04.014 – via ScienceDirect.
  9. ^ Vishwakarma, Ram A.; Menon, Anant K. (January 14, 2005). "Flip-flop of glycosylphosphatidylinositols (GPI's) across the ER". Chemical Communications (4): 453–455. doi:10.1039/B413196G. PMID 15654367 – via pubs.rsc.org.
  10. ^ A. Vishwakarma, Ram; Vehring, Stefanie; Mehta, Anuradha; Sinha, Archana; Pomorski, Thomas; Herrmann, Andreas; K. Menon, Anant (September 20, 2005). "New fluorescent probes reveal that flippase-mediated flip-flop of phosphatidylinositol across the endoplasmic reticulum membrane does not depend on the stereochemistry of the lipid". Organic & Biomolecular Chemistry. 3 (7): 1275–1283. doi:10.1039/B500300H. PMID 15785818 – via pubs.rsc.org.
  11. ^ Gannedi, Veeranjaneyulu; Ali, Asif; Singh, Parvinder Pal; Vishwakarma, Ram A. (June 19, 2020). "Total Synthesis of Phospholipomannan of Candida albicans". The Journal of Organic Chemistry. 85 (12): 7757–7771. doi:10.1021/acs.joc.0c00402. PMID 32425042 – via CrossRef.
  12. ^ "Nanoclusters of GPI-Anchored Proteins Are Formed by Cortical Actin-Driven Activity: Cell".
  13. ^ "Transbilayer Lipid Interactions Mediate Nanoclustering of Lipid-Anchored Proteins: Cell".
  14. ^ Bharate, Sandip B.; Sawant, Sanghapal D.; Singh, Parvinder Pal; Vishwakarma, Ram A. (August 14, 2013). "Kinase Inhibitors of Marine Origin". Chemical Reviews. 113 (8): 6761–6815. doi:10.1021/cr300410v. PMID 23679846 – via CrossRef.
  15. ^ Singh, Umed; Chashoo, Gousia; Khan, Sameer U.; Mahajan, Priya; Nargotra, Amit; Mahajan, Girish; Singh, Amarinder; Sharma, Anjna; Mintoo, Mubashir J.; Guru, Santosh Kumar; Aruri, Hariprasad; Thatikonda, Thanusha; Sahu, Promod; Chibber, Pankaj; Kumar, Vikas; Mir, Sameer A.; Bharate, Sonali S.; Madishetti, Sreedhar; Nandi, Utpal; Singh, Gurdarshan; Mondhe, Dilip Manikrao; Bhushan, Shashi; Malik, Fayaz; Mignani, Serge; Vishwakarma, Ram A.; Singh, Parvinder Pal (December 14, 2017). "Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model". Journal of Medicinal Chemistry. 60 (23): 9470–9489. doi:10.1021/acs.jmedchem.7b00663. PMID 29144137 – via CrossRef.
  16. ^ Mahale, Sachin; Bharate, Sandip B.; Manda, Sudhakar; Joshi, Prashant; Bharate, Sonali S.; Jenkins, Paul R.; Vishwakarma, Ram A.; Chaudhuri, Bhabatosh (November 26, 2014). "Biphenyl-4-carboxylic Acid [2-(1 H -Indol-3-yl)-ethyl]-methylamide (CA224), a Nonplanar Analogue of Fascaplysin, Inhibits Cdk4 and Tubulin Polymerization: Evaluation of in Vitro and in Vivo Anticancer Activity". Journal of Medicinal Chemistry. 57 (22): 9658–9672. doi:10.1021/jm5014743. PMID 25368960 – via CrossRef.
  17. ^ Bharate, Sandip B.; Kumar, Vikas; Jain, Shreyans K.; Mintoo, Mubashir J.; Guru, Santosh K.; Nuthakki, Vijay K.; Sharma, Mohit; Bharate, Sonali S.; Gandhi, Sumit G.; Mondhe, Dilip M.; Bhushan, Shashi; Vishwakarma, Ram A. (February 22, 2018). "Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor". Journal of Medicinal Chemistry. 61 (4): 1664–1687. doi:10.1021/acs.jmedchem.7b01765. PMID 29370702 – via CrossRef.
  18. ^ Srinivas, M.; Singh Pathania, Anup; Mahajan, Priya; Verma, Praveen K.; Chobe, Santosh S.; Malik, Fayaz A.; Nargotra, Amit; Vishwakarma, Ram A.; Sawant, Sanghapal D. (April 1, 2018). "Design and synthesis of 1,4-substituted 1H-1,2,3-triazolo-quinazolin-4(3H)-ones by Huisgen 1,3-dipolar cycloaddition with PI3Kγ isoform selective activity". Bioorganic & Medicinal Chemistry Letters. 28 (6): 1005–1010. doi:10.1016/j.bmcl.2018.02.032. PMID 29486969 – via ScienceDirect.
  19. ^ "Ram Vishwakama". scholar.google.co.in. Retrieved 2024-09-20.
  20. ^ https://sunpharma.com/wp-content/uploads/2020/12/Press-Release-Sun-Pharma-Science-Foundation-Award.pdf
  21. ^ https://pubs.acs.org/pb-assets/documents/masthead/jmcmar-masthead.pdf
  22. ^ https://ethnopharmacology.in/files/AwardSFEIndiacitation2016.pdf